The emerging role of the inflammasome in kidney diseases

Current Opinion in Nephrology and Hypertension

Volumn 23, Issue 3, 2014, Pages 204-210

  Chang, Anthony ^a   Ko, Kichul ^a   Clark, Marcus R ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

glomerulonephritis; NLRP3; proteinuria; tubulointerstitial inflammation

Indexed keywords

CRYOPYRIN; INFLAMMASOME; ANTIINFLAMMATORY AGENT; AUTACOID; CARRIER PROTEIN; NLRP3 PROTEIN, HUMAN;

ALBUMINURIA; DENDRITIC CELL; GLOMERULOPATHY; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY TUBULE CELL; MACROPHAGE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; IMMUNOLOGY; KIDNEY; KIDNEY DISEASES; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARRIER PROTEINS; HUMANS; INFLAMMASOMES; INFLAMMATION MEDIATORS; KIDNEY; KIDNEY DISEASES; SIGNAL TRANSDUCTION;

EID: 84898547262     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/01.mnh.0000444814.49755.90     Document Type: Review

References (48)

1. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10:417-426.
2. Fang L, Xie D, Wu X, et al. Involvement of endoplasmic reticulum stress in albuminuria induced inflammasome activation in renal proximal tubular cells. PLoS One 2013; 8:e72344.
3. Compan V, Baroja-Mazo A, López-Castejón G, et al. Cell volume regulation modulates NLRP3 inflammasome activation. Immunity 2012; 37:487-500.
4. Subramanian N, Natarajan K, Clatworthy MR, et al. The adaptor MAVS promotes NLRP3 mitochondrial localization and inflammasome activation. Cell 2013; 153:348-361.
5. Wen H, Miao EA, Ting JP-Y. Mechanisms of NOD-like receptor-associated inflammasome activation. Immunity 2013; 39:432-441.
6. Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. Nature 2012; 481:278-286.
7. Lamkanfi M, Dixit VM. Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol 2012; 28:137-161.
8. Rodrigue-Gervais IG, Saleh M. Caspases and immunity in a deadly grip. Trends Immunol 2013; 34:41-49.
9. Anders H-J, Muruve DA. The inflammasomes in kidney disease. J Am Soc Nephrol 2011; 22:1007-1018.
10. Lorenz G, Darisipudi MN, Anders H-J. Canonical and noncanonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis. Nephrol Dial Transplant 2014; 29:41-48.
11. Shigeoka AA, Mueller JL, Kambo A, et al. An inflammasome-independent role for epithelial-expressed Nlrp3 in renal ischemia-reperfusion injury. J Immunol 2010; 185:6277-6285.
12. Cao Q, Wang Y, Harris DCH. Pathogenic and protective role of macrophages in kidney disease. Am J Physiol Renal Physiol 2013; 305:F3-F11.
13. Nelson PJ, Rees AJ, Griffin MD, et al. The renal mononuclear phagocytic system. J Am Soc Nephrol 2012; 23:194-203.
14. Vilaysane A, Chun J, Seamone ME, et al. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol 2010; 21:1732-1744.
15. Correa-Costa M, Braga TT, Semedo P, et al. Pivotal role of Toll-like receptors 2 and 4, its adaptor molecule MyD88, and inflammasome complex in experimental tubule-interstitial nephritis. PLoS One 2011; 6:e29004.
16. Chen K, Zhang J, Zhang W, et al. ATP-P2X4 signaling mediates NLRP3 inflammasome activation: a novel pathway of diabetic nephropathy. Int J Biochem Cell Biol 2013; 45:932-943.
17. Mulay SR, Kulkarni OP, Rupanagudi KV, et al. Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1b secretion. J Clin Invest 2013; 123:236-246.
18. Knauf F, Asplin JR, Granja I, et al. NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy. Kidney Int 2013; 84:895-901.
19. Darisipudi MN, Thomasova D, Mulay SR, et al. Uromodulin triggers IL-1bdependent innate immunity via the NLRP3 inflammasome. J Am Soc Nephrol 2012; 23:1783-1789.
20. LabbéK, McIntire CR, Doiron K, et al. Cellular inhibitors of apoptosis proteins cIAP1 and cIAP2 are required for efficient caspase-1 activation by the inflammasome. Immunity 2011; 35:897-907.
21. Vince JE, Wong WW-L, Gentle I, et al. Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation. Immunity 2012; 36:215-227.
22. Kim H-J, Lee DW, Ravichandran K, et al. NLRP3 inflammasome knockout mice are protected against ischemic but not cisplatin-induced acute kidney injury. J Pharmacol Exp Ther 2013; 346:465-472.
23. Lameire N. The pathophysiology of acute renal failure. Crit Care Clin 2005; 21:197-210.
24. Lichtnekert J, Kulkarni OP, Mulay SR, et al. Anti-GBM glomerulonephritis involves IL-1 but is independent of NLRP3/ASC inflammasome-mediated activation of caspase-1. PLoS One 2011; 6:e26778.
25. Deplano S, Cook HT, Russell R, et al. P2X7 receptor-mediated Nlrp3- inflammasome activation is a genetic determinant of macrophagedependent crescentic glomerulonephritis. J Leukoc Biol 2013; 93:127-134.
26. Zhao J, Wang H, Dai C, et al. P2X7 blockade attenuates murine lupus nephritis by inhibiting activation of the NLRP3/ASC/Caspase 1 pathway. Arthritis Rheum 2013; 65:3176-3185.
27. Zhao J, Zhang H, Huang Y, et al. Bay11-7082 attenuates murine lupus nephritis via inhibiting NLRP3 inflammasome and NF-kB activation. Int Immunopharmacol 2013; 17:116-122.
28. Zhu F-G, Jiang W, Bhagat L, et al. A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice. Autoimmunity 2013; 46:419-428.
29. Tsai P-Y, Ka S-M, Chang J-M, et al. Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation. Free Radic Biol Med 2011; 51:744-754.
30. Yang S-M, Ka S-M, Hua K-F, et al. Antroquinonol mitigates an accelerated and progressive IgA nephropathy model in mice by activating the Nrf2 pathway and inhibiting T cells and NLRP3 inflammasome. Free Radic Biol Med 2013; 61C:285-297.
31. Hua K-F, Yang S-M, Kao T-Y, et al. Osthole mitigates progressive IgA nephropathy by inhibiting reactive oxygen species generation and NF-kB/ NLRP3 pathway. PLoS One 2013; 8:e77794.
32. Zhang C, Boini KM, Xia M, et al. Activation of Nod-like receptor protein 3 inflammasomes turns on podocyte injury and glomerular sclerosis in hyperhomocysteinemia. Hypertension 2012; 60:154-162.
33. Abais JM, Zhang C, Xia M, et al. NADPH oxidase-mediated triggering of inflammasome activation in mouse podocytes and glomeruli during hyperhomocysteinemia. Antioxid Redox Signal 2013; 18:1537-1548.
34. Abais JM, Xia M, Li G, et al. Contribution of endogenously produced reactive oxygen species to the activation of podocyte NLRP3 inflammasomes in hyperhomocysteinemia. Free Radic Biol Med 2014; 67:211-220.
35. Solini A, Menini S, Rossi C, et al. The purinergic 2X7 receptor participates in renal inflammation and injury induced by high-fat diet: possible role of NLRP3 inflammasome activation. J Pathol 2013; 231:342-353.
36. Goldwich A, Burkard M, Olke M, et al. Podocytes are nonhematopoietic professional antigen-presenting cells. J Am Soc Nephrol 2013; 24:906-916.
37. Working Group of the International IgA Nephropathy Network the Renal Pathology Society. Roberts ISD, Cook HT, Troyanov S, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76:546-556.
38. Hsieh C, Chang A, Brandt D, et al. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res 2011; 63:865-874.
39. Iseki K, Iseki C, Ikemiya Y, Fukiyama K. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int 1996; 49:800-805.
40. Erkan E, Devarajan P, Schwartz GJ. Mitochondria are the major targets in albumin-induced apoptosis in proximal tubule cells. J Am Soc Nephrol 2007; 18:1199-1208.
41. Nishi Y, Satoh M, Nagasu H, et al. Selective estrogen receptor modulation attenuates proteinuria-induced renal tubular damage by modulating mitochondrial oxidative status. Kidney Int 2013; 83:662-673.
42. Silbiger S, Neugarten J. Gender and human chronic renal disease. Gend Med 2008; 5 (Suppl. A):S3-S10.
43. Okamura K, Dummer P, Kopp J, et al. Endocytosis of albumin by podocytes elicits an inflammatory response and induces apoptotic cell death. PLoS One 2013; 8:e54817.
44. Wang W,Wang X, Chun J, et al. Inflammasome-independentNLRP3 augments TGF-b signaling in kidney epithelium. J Immunol 2013; 190:1239-1249.
45. Gewin L, Zent R. How does TGF-b mediate tubulointerstitial fibrosis? Semin Nephrol 2012; 32:228-235.
46. Schiffer M, Bitzer M, Roberts IS, et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001; 108:807-816.
47. Wharram BL, Goyal M, Wiggins JE, et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005; 16:2941-2952.
48. Kriz W, LeHir M. Pathways to nephron loss starting from glomerular diseases - insights from animal models. Kidney Int 2005; 67:404-419.